Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease
ChiCTR2200067219Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Jan 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of colchicine in dermatomyositis (DM), interstitial lung disease (ILD) and dermatomyositis-associated interstitial lung disease (DM-ILD) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: 6-month overall survival. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
dermatomyositis (DM)interstitial lung disease (ILD)dermatomyositis-associated interstitial lung disease (DM-ILD)
Beyond the preview
Go deeper on ChiCTR2200067219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067219.